[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370732-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-370732-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","deciphering-cancer-therapy-resistancevia-patient-level-single-cell-transcriptomics-with-cellresdb-authoritative-research-article-overview","Deciphering cancer therapy resistancevia patient-level single-cell transcriptomics with CellResDB - Authoritative research article overview","","Cancer therapy resistance remains a major challenge because existing resources often rely on bulk RNA-seq, lack single-cell resolution, and provide limited clinical annotations, which constrains patient-level mechanistic studies of the tumor microenvironment (TME). CellResDB is introduced as a patient-derived platform containing nearly 4.7 million cells from 1391 samples across 24 cancer types, with extensive TME feature annotations linked to therapy resistance. An accompanying CellResDB-Robot improves data retrieval and analysis, and the work highlights an experimental protocol for applying large language models (LLMs) in biomedical databases.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/deciphering-cancer-therapy-resistancevia-patient-level-single-cell-transcriptomics-with-cellresdb-authoritative-research-article-overview/370732/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/deciphering-cancer-therapy-resistancevia-patient-level-single-cell-transcriptomics-with-cellresdb-authoritative-research-article-overview/370732.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":30},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"Why are existing databases insufficient for studying therapy resistance at the patient level?","Question",{"text":62,"@type":63},"Existing databases commonly depend on bulk RNA-seq, lack single-cell resolution, and offer limited clinical annotations, making them inadequate for in-depth exploration of TME dynamics in therapy resistance.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"What does CellResDB provide and how large is its coverage?",{"text":67,"@type":63},"CellResDB is a patient-derived platform with nearly 4.7 million cells from 1391 patient samples across 24 cancer types, fully annotated and searchable for TME features related to therapy resistance.",{"name":69,"@type":60,"acceptedAnswer":70},"How does CellResDB improve usability for researchers beyond the raw datasets?",{"text":71,"@type":63},"CellResDB includes an intelligent robot, CellResDB-Robot, designed to simplify user interactions, enabling intuitive data retrieval and analysis. It also offers comprehensive analyses of TME composition, functional enrichment, and cell communication related to therapy.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},370732,1792162272,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":30,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","communications biology Article  \nA Nature Portfolio journal  \n[https://doi.org/10.1038/s42003-025-08457-2](https://doi.org/10.1038/s42003-025-08457-2)  \nDeciphering cancer therapy resistancevia patient-level single-cell transcriptomics with CellResDB  \n Check for updates  \nTianyuan Liu 1,2,6, Huiyuan Qiao3,6, Liping Ren4, Xiucai Ye 2 , Quan Zou 5  & Yang Zhang 1   \nCancer therapy resistance remains a major challenge, with limited resources available for systematically studying its underlying mechanisms at the patient level. The existing databases are either restricted to bulk RNA-seq data, lack single-cell resolution, or provide limited clinical annotations, making them insufﬁcient for in-depth exploration of the tumor microenvironment (TME) dynamics in therapy resistance. To bridge this gap, we present CellResDB, a patient-derived platform comprising nearly 4.7 million cells from 1391 patient samples across 24 cancer types. CellResDB provides comprehensive annotations of TME features linked to therapy resistance. To enhance accessibility, we include an intelligent robot, CellResDB-Robot, which facilitates intuitive data retrieval and analysis. In summary, CellResDB represents a valuable resource for cancer therapy and providesan experimental protocol for applying large language models (LLMs) within the biomedical database. CellResDB is freely available at [https://cellknowledge.com.cn/cellresponse](https://cellknowledge.com.cn/cellresponse).  \nIn recent decades, there has been signiﬁcant progress in cancer treatment, including chemotherapy, targeted therapy, and immunotherapy, leading to improved survival rates for many cancer types1–4. However, many patients do not respond to treatment or experience relapse, with immunotherapy response rates typically ranging from 20% to 40%5,6, and targeted therapies showing high variation between 25% and 75%7. The tumor microenvironment(TME), a complex ecosystem ofcancerous and non-cancerous cells, plays a pivotal role in therapy resistance. The TME has been shown to interact with the therapeutic approach and inﬂuence treatment response8–11, often involving communication between TandB lymphocytes12. Therefore, understanding the cellular and molecular dynamicsoftheTME is crucial for overcoming resistance and enhancing personalized cancer therapies.  \nThe development of single-cell RNA sequencing (scRNA-seq) has revolutionized our ability to dissect the complexity and heterogeneity of the TME with cellular resolution13–16. This technology enables the precise proﬁling of cells within the TME, uncovering the cellular composition17, cell communication18, 19, and transcriptional phenotypes20 that may inﬂuence treatment response. When combined with longitudinal sampling, scRNAseq allows researchers to track dynamic changes over time, revealing potential mechanisms of resistance and novel therapeutic targets8,21. Ultimately, by elucidating the intricate cellular and molecular landscape of  \nTME, we can accelerate the development ofmore effective and personalized cancer treatments22. During the past years, several databases have been developed to support clinical research in the ﬁeld of cancer, including CancerSCEM 2.023, TISCH224, Curated Cancer Cell Atlas25, ICBatlas26, ICBcomb27, and DRMref27. Among these, CancerSCEM 2.0, TISCH2, and Curated Cancer Cell Atlas have compiled extensive scRNA-seq data from various cancer types, comprising41,900cells, more than 6million cells, and 2.5 million cells, respectively. Other databases, such as ICBatlas and ICBcomb, focus on immune checkpoint blockade (ICB) therapies but rely on bulk RNA-seq data, lacking single-cell resolution. DRMref, which focuses on cancer treatment response, includes42single-cell datasets, among which only 22 datasets are derived from patient samples, limiting its value as a comprehensive reference for therapy resistance studies. Consequently, thereis still a need for large-scale, well-annotated, integrated scRNA-seq databases dedicate","cbCaiu02fEFswLTG","https://ap.wps.com/l/cbCaiu02fEFswLTG","pdf",4070524,11,"English","# Introduction\n# CellResDB Resource Design and Coverage\n# Comparative Landscape of Existing Databases\n# Analyses, Access, and CellResDB-Robot\n# Availability and Impact","[{\"question\":\"Why are existing databases insufficient for studying therapy resistance at the patient level?\",\"answer\":\"Existing databases commonly depend on bulk RNA-seq, lack single-cell resolution, and offer limited clinical annotations, making them inadequate for in-depth exploration of TME dynamics in therapy resistance.\"},{\"question\":\"What does CellResDB provide and how large is its coverage?\",\"answer\":\"CellResDB is a patient-derived platform with nearly 4.7 million cells from 1391 patient samples across 24 cancer types, fully annotated and searchable for TME features related to therapy resistance.\"},{\"question\":\"How does CellResDB improve usability for researchers beyond the raw datasets?\",\"answer\":\"CellResDB includes an intelligent robot, CellResDB-Robot, designed to simplify user interactions, enabling intuitive data retrieval and analysis. It also offers comprehensive analyses of TME composition, functional enrichment, and cell communication related to therapy.\"}]","Deciphering cancer therapy resistancevia patient-level single-cell transcriptomics with CellResDB - Authoritative research article overview | PDF",1790190120,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0a6d8fa708a89ec88262bb5359dcaf4.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d92b7cdb8d26f084f48c11033a9d102.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7683eb889ea8b7c3900fb6c8f0ede819.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/069bd9e5483551b48b860e25e4ec8c7c.webp",980,1301]